











Third French International Symposium on CAR T Cells (CARTday)

Organized by the Faculty of Medicine, the Lille University Hospital Under the auspices of the Chronic Malignancies Working Party of the EBMT and the Francophone Society of Bone Marrow transplantation and Cellular Therapy (SFGM-TC)

Thursday, January 17th, 2019

Faculté de Médecine-pôle recherche, 1 place de Verdun, 59000 Lille, France

08:30 - Welcome and registration

09:15 - Introduction

Didier Gosset, Dean of the Faculty of Medicine,

Ibrahim Yakoub-Agha and Bruno Quesnel

Session 1: CAR-T Overview - Chairs: Bruno Quesnel, Salomon Manier & Olivier Boyer

- 9:30- Enhanced Anti-lymphoma Activity of CAR19-iNKT

Anastasios Karadimitris (London, UK)

- 10:00- Phosphoproteomic analysis of chimeric antigen receptor signaling

Alex Salter (Seattle, USA)
10:30- Development of gene- edited allogeneic CAR T (UCAR-T)

Stephan Depil (Cellectis, France)

10:50- CAR T cells with suicide gene

Aaron Foster (Bellicum, Houston, USA)

Session 2: complications - Chairs: Ibrahim Yakoub-Agha & Mohamad Mohty

- 11:10- Monitoring for long-term complications of CAR T therapies Shannon Maude (Philadelphia, USA)

- 11:40- Role of Monocyte-derived IL-1 and IL-6 in CRS & neurotoxicity

Fabio Ciceri (Milano, Italie)

12:00- Long-term follow-up data on "Factors impacting duration of response to CD19 CAR-T cells in B cell malignancies".

Cameron Turtle (Seattle, USA)

12h30 - Lunch

Session 3: Regulatory issues - Chairs: André Baruchel & Christian Chabannon

- 13:30 - Landscape of CAR T cells in France

Muriel Dahan (the National Institute of Cancer – INCa, France)

- 13:50- How do cooperative groups see their role in CAR-T Cell evaluation?

André Baruchel (Paris, France)

- 14:10- EBMT strategy for immune effector cells

Jürgen Kuball (Utrecht, Netherlands)

- 14:40- The Why, What, and How of the New JACIE standards for immune effector cells. Eoin McGrath (EBMT)

15h10 -Break

Session 4: Clinical data - Chairs: Thierry Facon & Franck Morschhauser

- 15:30- Solid tumors

Stephen Gottschalk (Memphis, USA)

- 16:00- Lymphoid malignancies

Armin Ghobadi (St Louis, USA)

16:30- Myeloid malignancies

Rawan Faramand (Tampa, USA)

- 17:00- **Multiple myeloma** *Ibrahim Yakoub-Agha (Lille, France)*

- 17H30 – Conclusion I. Yakoub-Agha